Cargando…
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An extensive Medline, Cochrane database, and Embase search for “exenatide,” “liraglutide,” “albiglutide,” “semaglutide,” and “lix...
Autores principales: | Monami, Matteo, Dicembrini, Ilaria, Marchionni, Niccolò, Rotella, Carlo M., Mannucci, Edoardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362858/ https://www.ncbi.nlm.nih.gov/pubmed/22675341 http://dx.doi.org/10.1155/2012/672658 |
Ejemplares similares
-
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011) -
Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012) -
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015) -
Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
por: Mossello, Enrico, et al.
Publicado: (2011) -
Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
por: Monami, Matteo, et al.
Publicado: (2011)